Ryman Healthcare (NZSE:RYM): Reassessing Valuation After Half-Year Revenue Growth Turns Profit into Net Loss

Simply Wall St.

Dec 11, 2025

Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590175605"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590175605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590175605?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","is_english":true,"pubTime":"2025-12-11 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590175605","market":"nz","top_or_hot":-1,"title":"Ryman Healthcare (NZSE:RYM): Reassessing Valuation After Half-Year Revenue Growth Turns Profit into Net Loss","media":"Simply Wall St.","content":"<div>\n<p>Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-reassessing-valuation-after-half-ye\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ryman Healthcare (NZSE:RYM): Reassessing Valuation After Half-Year Revenue Growth Turns Profit into Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRyman Healthcare (NZSE:RYM): Reassessing Valuation After Half-Year Revenue Growth Turns Profit into Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-11 20:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-reassessing-valuation-after-half-ye><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-reassessing-valuation-after-half-ye\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYM.NZ","symbol_name":"Ryman Healthcare Limited Ordinary Shares","start_time":0,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-reassessing-valuation-after-half-ye","article_id":"2590175605","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-reassessing-valuation-after-half-ye","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590175605","pubTimestamp":1765456378,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss.\nSee our latest analysis for Ryman Healthcare.\nThe NZ$2.88 share price reflects a mixed story, with a solid 90 day share price return of 15.66% but a steep year to date share price decline and weak multi year total shareholder returns. This hints that sentiment is only cautiously improving after the earnings setback.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RYM.NZ":"Ryman Healthcare Limited Ordinary Shares","XLV":"健康照护类股ETF-SPDR","RYM":"RYTHM Inc."},"translate_title":"Ryman Healthcare（NZSE：RYM）：半年收入增长后重新评估估值将利润转为净亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYM.NZ":1.5,"XLV":1.5,"RYM":1.5},"content_text":"Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis for Ryman Healthcare. The NZ$2.88 share price reflects a mixed story, with a solid 90 day share price return of 15.66% but a steep year to date share price decline and weak multi year total shareholder returns. This hints that sentiment is only cautiously improving after the earnings setback. If this earnings wobble has you rethinking your sector exposure, it could be a good moment to compare Ryman with other healthcare stocks and see where the market is pricing quality and recovery potential. With the share price still well below recent years but modestly under analyst targets, the key question now is whether Ryman is undervalued after its profit setback, or if the market is already pricing in a meaningful recovery. AdvertisementMost Popular Narrative: 10.7% Undervalued Against the last close of NZ$2.88, the most widely followed narrative points to fair value closer to NZ$3.23, framing Ryman as modestly mispriced and highly dependent on a profitability turnaround.  The analysts have a consensus price target of NZ$2.825 for Ryman Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of NZ$3.5, and the most bearish reporting a price target of just NZ$2.51.  Read the complete narrative. Want to see what justifies a dramatic swing from deep losses to healthy margins and rising earnings, plus a lower future earnings multiple, all at once? Dive in to uncover the specific growth, margin and valuation assumptions that underpin this fair value call. Result: Fair Value of $3.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on leadership rebuilding trust and managing heavy debt, as any stumble on governance or refinancing could quickly sour sentiment again. Find out about the key risks to this Ryman Healthcare narrative. Another Angle on Valuation While the consensus narrative leans toward Ryman being modestly undervalued, the price to sales ratio tells a harsher story. At 3.6x sales versus 1.3x for the Oceanic healthcare sector and a 1.5x fair ratio, Ryman screens as expensive. This raises the question: what exactly is the market already pricing in? See what the numbers say about this price — find out in our valuation breakdown. NZSE:RYM PS Ratio as at Dec 2025 Build Your Own Ryman Healthcare Narrative If you see the story differently or want to dig into the numbers yourself, you can build a personalised view in just a few minutes: Do it your way. A great starting point for your Ryman Healthcare research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Ryman might be on your radar, but do not leave potential gains on the table when a few focused screeners can surface your next standout opportunity.  Seize potential mispricings by using these 908 undervalued stocks based on cash flows to pinpoint companies where cash flows suggest the market has not fully caught up yet. Capitalize on technological disruption with these 26 AI penny stocks, spotting early movers riding structural demand for intelligent software and automation. Harness steady income potential via these 12 dividend stocks with yields > 3%, where higher yields pair with fundamentals strong enough to support consistent payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}